Glaxo CEO: Price Pressure Continues in United States

The video discusses the performance and future outlook of various divisions within a pharmaceutical company. It covers the respiratory market, highlighting a shift from Advair to new products and the impact of generics. The consumer division's growth trajectory towards 20% margins is analyzed, emphasizing synergies with pharmaceuticals. The oncology section outlines ongoing developments and future potential, with a focus on epigenetics and immuno-oncology.

What is the expected trend for respiratory products throughout the year?

• A shift back to Advair dominance

• Growth driven by new products

• Stability with no significant changes

• A decline in sales due to price pressure

What is the target margin percentage for the consumer division?

• 25%

• 30%

• 20%

• 15%

Why is the consumer healthcare division kept within the pharmaceutical company?

• It operates independently with no synergies

• It is a small, non-capital intensive business

• It has no connection to pharmaceutical products

• It benefits from shared manufacturing and regulatory oversight

What area is GSK focusing on for future oncology products?

• Cardiology

• Neurology

• Epigenetic and immuno-oncology

• Dermatology

What strategic decision did GSK make regarding old generation oncology products?

• To invest more in them

• To sell them off

• To merge them with new products

• To discontinue them without selling